Darryl K. Fedorak

Edmonton, AB T6G2X8, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study.

Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study.

Journal: Inflammatory bowel diseases

Published: January 29, 2016

Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study.

Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study.

Journal: Canadian journal of gastroenterology & hepatology

Published: December 16, 2015

Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study.

Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study.

Journal: Canadian journal of gastroenterology & hepatology

Published: June 13, 2015

Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy.

Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy.

Journal: Inflammatory bowel diseases

Published: May 20, 2015

A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels.

A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels.

Journal: Canadian journal of gastroenterology & hepatology

Published: February 24, 2015

Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.

Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.

Journal: Journal of clinical gastroenterology

Published: November 13, 2014

Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease.

Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease.

Journal: Alimentary pharmacology & therapeutics

Published: June 24, 2014

Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.

Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.

Journal: Journal of Crohn's & colitis

Published: March 31, 2014

Prevalence of Epstein-Barr Virus in a population of patients with inflammatory bowel disease: a prospective cohort study.

Prevalence of Epstein-Barr Virus in a population of patients with inflammatory bowel disease: a prospective cohort study.

Journal: Alimentary pharmacology & therapeutics

Published: April 21, 2013

Showing 1-9 of 9

Last Updated: 09/26/2026